SCHEMBL4125257

SCHEMBL4125257

O=C(O)c1cccc(/C=C2\SC(=S)N(Cc3ccc4c(c3)OCO4)C2=O)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 3/20 0.65
▸ KMT2A Q03164 3/20 0.65
▸ CTDSP1 Q9GZU7 2/20 0.65
▸ MAPK1 P28482 2/20 0.65
▸ PTPN7 P35236 2/20 0.63
▸ PTPN12 Q05209 2/20 0.63
▸ GPR35 Q9HC97 2/20 0.63
▸ PTPN22 Q9Y2R2 2/20 0.63
▸ DUSP22 Q9NRW4 1/20 0.61
▸ PTPN1 P18031 5/20 0.59
▸ POLB P06746 1/20 0.59
▸ BLM P54132 1/20 0.59
▸ NLRP3 Q96P20 3/20 0.57
▸ PSMD14 O00487 1/20 0.57
▸ MMP2 P08253 1/20 0.57
▸ GPR55 Q9Y2T6 1/20 0.57
▸ ENPP2 Q13822 1/20 0.56
▸ ATM Q13315 1/20 0.55
▸ DDX3X O00571 1/20 0.55
▸ HPGD P15428 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4125259 1.00 MEN1 (0.65) MEN1KMT2ACTDSP1MAPK1PTPN7
SCHEMBL4125640 0.90 PTPN1 (0.67) MEN1KMT2ACTDSP1MAPK1PTPN7
SCHEMBL4125637 0.90 PTPN1 (0.67) MEN1KMT2ACTDSP1MAPK1PTPN7
SCHEMBL4125376 0.88 MEN1 (0.69) MEN1KMT2ACTDSP1MAPK1PTPN7
SCHEMBL4125372 0.88 MEN1 (0.69) MEN1KMT2ACTDSP1MAPK1PTPN7
SCHEMBL4125367 0.88 MEN1 (0.69) MEN1KMT2ACTDSP1MAPK1PTPN7
SCHEMBL4142279 0.87 MAPK1 (0.67) MEN1KMT2ACTDSP1MAPK1PTPN7
SCHEMBL4142283 0.87 MAPK1 (0.67) MEN1KMT2ACTDSP1MAPK1PTPN7
SCHEMBL4138637 0.86 MAPK1 (0.72) MEN1KMT2ACTDSP1MAPK1PTPN7
SCHEMBL4138638 0.86 MAPK1 (0.72) MEN1KMT2ACTDSP1MAPK1PTPN7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090247516-A1 3- (BENZO [D] [1,3] DIOXOL-5-YLMETHYL) -4- (THIO) OXO-2- (THIO) OXO-AZOLIDIN-5-YLIDENE DERIVATIVES AS ANTIBACTERIAL AGENTS KOTNIK MIHA 2009-10-01 — — US disclosed
US-20090247516-A1 3- (BENZO [D] [1,3] DIOXOL-5-YLMETHYL) -4- (THIO) OXO-2- (THIO) OXO-AZOLIDIN-5-YLIDENE DERIVATIVES AS ANTIBACTERIAL AGENTS KOTNIK MIHA 2009-10-01 — — US disclosed
EP-1916249-A1 3-(benzo[d][1,3]dioxol-5-ylmethyl)-4-(thio)oxo-2-(thio)oxo-azolidin-5-ylidene derivatives as antibacterial agents LEK Pharmaceuticals D.D. (SI) 2008-04-30 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247516-A1 3- (BENZO [D] [1,3] DIOXOL-5-YLMETHYL) -4- (THIO) OXO-2- (THIO) OXO-AZOLIDIN-5-YLIDENE DERIVATIVES AS ANTIBACTERIAL AGENTS XDH, TXLNA, Q6ZSR9 MEN1 2336/4885KMT2A 1459/4885CTDSP1 3586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback